Alpha Cognition Inc. Comm...

5.50
0.19 (3.58%)
At close: Mar 28, 2025, 3:59 PM
5.51
0.14%
After-hours: Mar 28, 2025, 06:11 PM EDT

Company Description

Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury.

It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases.

The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021.

Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.

Alpha Cognition Inc. Common Stock
Alpha Cognition Inc. Common Stock logo
Country CA
IPO Date n/a
Industry Financial - Conglomerates
Sector Financial Services
Employees 5
CEO Michael E. McFadden B.B.A.

Contact Details

Address:
750 West Pender Street
Vancouver, BC
CA
Website https://www.alphacognition.com

Stock Details

Ticker Symbol ACOG
Exchange NASDAQ
Fiscal Year n/a
Reporting Currency USD
CIK Code 0001655923
CUSIP Number n/a
ISIN Number CA02074J5017
Employer ID 00-0000000
SIC Code 2836

Key Executives

Name Position
Michael E. McFadden B.B.A. Chief Executive Officer & Director
Henry Du CPA Vice President of Finance & Accounting and Interim Chief Financial Officer
Lauren D'Angelo M.B.A. Chief Operating Officer
Dr. Denis G. Kay Ph.D. Chief Scientific Officer
Kenneth Anthony Cawkell B.A., LL.B. Founder, Consultant, Corporate Secretary & Director

Latest SEC Filings

Date Type Title
Feb 27, 2025 4 Filing
Feb 27, 2025 4 Filing
Feb 27, 2025 4 Filing
Feb 27, 2025 4 Filing
Feb 27, 2025 4 Filing
Feb 27, 2025 4 Filing
Feb 27, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G Filing
Feb 14, 2025 SCHEDULE 13G Filing
Feb 13, 2025 SCHEDULE 13G/A [Amend] Filing